Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Benj Gallander
Theragenics CorpTGXPAST TOP PICKDec 06, 2011
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
$1.66
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
PAST TOP PICK
PAST TOP PICK
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
Benj GallanderOwned
biotechnologypharmaceutical
TOP PICK
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
Benj GallanderOwned
biotechnologypharmaceutical
TOP PICK
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
Benj GallanderOwned
biotechnologypharmaceutical
WEAK BUY
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
Benj GallanderOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
Benj GallanderOwned
biotechnologypharmaceutical
TOP PICK
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
Ben StadelmannOwned
biotechnologypharmaceutical
TOP PICK
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
Ben StadelmannOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
Benj GallanderOwned
biotechnologypharmaceutical
TOP PICK
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
Ben StadelmannOwned
biotechnologypharmaceutical
TOP PICK
TOP PICK
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
Benj GallanderOwned
biotechnologypharmaceutical
